Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCAGN01876 |
Synonyms | |
Therapy Description |
INCAGN01876 is an activating monoclonal antibody that binds to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), which leads to activation of GITR and potentially results in activation of anti-tumor immunity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCAGN01876 | INCAGN1876|INCAGN-1876|INCAGN 1876 | GITR Antibody 7 | INCAGN01876 is an activating monoclonal antibody that binds to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), which leads to activation of GITR and potentially results in activation of anti-tumor immunity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |